KY-0201

N/A

Report date: 2024/04/15 14:25:31

Base Information

Drug NameKY-0201
Drug Alias NameKY-0201
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed death-ligand 1 blockersCluster of differentiation 47 inhibitors
TargetsProgrammed death-ligand 1Cluster of differentiation 47
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A